Former Leaders of Thorne HealthTech and Tempus Launch Brain Health and Wellness Company BEVIMI at Inaugural CG Well Summit

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- CG WELL SUMMIT –  The leaders of brain health and wellness company BEVIMI today announced the launch of their company as part of the inaugural CG Well Summit. Convened by leading independent, full-service financial services firm Canaccord Genuity Group, this global summit unites thought leaders and key deal makers in the consumer health and wellness space. This morning's opening keynote will be delivered by BEVIMI Co-Founder and President Joel Dudley, Ph.D.

Kicking off the summit, Dudley's "Wellness 3.0: Charting a New Path for Personalized and Preventative Health" talk will address the transition from sick care to true health care that BEVIMI is designed to lead. Drawing from his vast qualifications and experiences detailed below, Dudley will reveal how AI, precision health, and advanced diagnostics can finally unlock lasting outcomes and empower people to thrive.

Later today, BEVIMI Co-Founder and CEO Paul Jacobson will join the summit's "Demonstrable Consumer Outcomes: Proof Over Promises and the Brands Driving Outcomes" expert panel discussion. As the former CEO of Thorne HealthTech, Jacobson led the company through 15 years of expansion – growing sales roughly 10-times, taking the venture public, then steering its go-private transaction. For this panel, he will join leaders in women's health, longevity, gut, and brain health that are delivering real outcomes and making science-backed solutions accessible.  

BEVIMI's Mission and Future
Serving its mission of becoming a global leader in the advancement of cognitive longevity, BEVIMI is being built on a foundation of scientific rigor, innovation, and preventative health. Together with a rapidly growing staff representing proven leaders in the field, from their headquarters in Greenwich, Connecticut, Jacobson and Dudley are actively developing a platform for products focused on targeting neuroinflammation and cognitive performance across multiple indications and markets.

Today, the company is also revealing key details about its first product, which is currently slated for launch early next year. Designed as nutritional support for individuals at high risk of – or in preclinical stages of – Alzheimer's disease, the product represents a breakthrough in cognitive health innovation. While a solid scientific foundation already exists for the product's individual ingredients, it will enter an Institutional Review Board-approved, randomized, double-blind, placebo-controlled clinical study over the months ahead. The study's primary objective is safety and tolerability, while secondary and exploratory measures will assess changes across a pre-specified biomarker panel relevant to Alzheimer's pathophysiology.

According to BEVIMI's co-founders, cognitive decline is a multifaceted process that requires addressing several underlying mechanisms simultaneously. Their flagship product aims to be the first of its kind to deliver clinically validated, bioactive ingredients – including hard-to-deliver hydrophobic compounds – at meaningful levels in a conveniently dosed 2-ounce beverage.

"Brain health is the new heart health," Jacobson began. "Consumers are elevating cognitive wellness to a daily priority, and the underlying science has matured. BEVIMI's first formulation is a multi-ingredient systems approach, intentionally mapped to four well-characterized pathways in Alzheimer's biology. Each component was selected based on convergent human safety data and preclinical evidence, with attention to bioavailability, blood brain barrier engagement proxies, and complementary mechanism of action. We founded BEVIMI with leading scientists to bring pharmaceutical-style rigor – target mapping, dose justification, and pre-specified endpoints – to evidence-informed nutrition."

"Starting soon," Dudley added, "BEVIMI will begin providing science-based nutritional support, education, and AI-driven insights to help people who are seeking proactive solutions for cognitive decline. Long term, our proprietary technology and focus on dampening neuroinflammation, supporting amyloid-beta (Aβ) proteostasis and clearance, reinforcing blood-brain barrier integrity, and optimizing gut-microbiome-derived metabolites that influence brain signaling, will support improved outcomes across a wide spectrum of cognitive challenges, including focus, mood, sleep, and mental acuity."

With its debut at the CG Well Summit, BEVIMI enters the wellness and brain health market with a strong scientific foundation, and a clear commitment to supporting cognitive longevity for people worldwide.

To stay informed about BEVIMI and its offerings – including its upcoming product launch – visit https://www.mybevimi.com.

Joel Dudley is the Co-Founder and President of BEVIMI. He previously served as General Partner at Innovation Endeavors, a leading technology venture capital firm; and as Chief Scientific Officer at Tempus, where he helped scale AI- and data-driven platforms in healthcare. Before Tempus, Dudley was an Associate Professor of Genetics & Genomic Sciences and the Founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai, and also Executive Vice President for Precision Health for the Mount Sinai Health System. An experienced entrepreneur, he co-founded Onegevity Health (acquired by Thorne) and NuMedii, a pioneer in machine-learning-based drug discovery. Dudley has authored 200+ peer-reviewed papers, with coverage in the New York Times, Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and others. He holds a B.S. in Microbiology from Arizona State University and M.S./Ph.D. in Biomedical Informatics from the Stanford University School of Medicine.

Paul Jacobson is the Co-Founder and Chief Executive Officer of BEVIMI, bringing more than two decades of operating and capital-markets leadership. Most recently, Jacobson served as CEO of Thorne HealthTech, where he led the company through 15 years of expansion. Prior to that, he was a private investor who served on various healthcare and biotechnology company boards of directors, including Progenics Pharmaceuticals. Earlier in his career, Jacobson was a Partner and Co-Head of the Liquid Capital Markets group at Goldman Sachs. He holds an M.B.A. from Washington University and a B.A. in English and Economics from Vanderbilt University.

About BEVIMI
As a health and wellness company dedicated to advancing cognitive longevity and performance, BEVIMI develops proprietary, science-based nutritional products, support, and education. Launched in 2025 by leading scientists to bring pharmaceutical-style rigor to evidence-informed nutrition, BEVIMI is committed to supporting cognitive longevity for people worldwide. To learn more, please visit https://www.mybevimi.com.

NOTE TO EDITORS: Image to accompany this story here: https://darnellworks.com/bevimi/media/jd-pj-m.jpg [Caption (L-R): BEVIMI Co-Founder and President Joel Dudley, and Co-Founder and Chief Executive Officer Paul Jacobson.]

SOURCE BEVIMI